View clinical trials related to Palmoplantar Pustulosis.
Filter by:The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.